Stock Scorecard
Stock Summary for Akebia Therapeutics Inc (AKBA) - $2.84 as of 9/18/2025 7:14:36 PM EST
Total Score
7 out of 30
Safety Score
38 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AKBA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AKBA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AKBA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AKBA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AKBA (38 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AKBA
Financial Details for AKBA
Company Overview |
|
|---|---|
| Ticker | AKBA |
| Company Name | Akebia Therapeutics Inc |
| Country | USA |
| Description | Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to advancing innovative therapies for chronic kidney disease. With a robust pipeline that focuses on both the development and commercialization of kidney-related treatments, Akebia is committed to addressing the unmet medical needs of patients with renal conditions. The company's strategic initiatives leverage cutting-edge research and collaborations to enhance patient outcomes and expand its market presence in the evolving healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 2.84 |
| Price 4 Years Ago | 2.26 |
| Last Day Price Updated | 9/18/2025 7:14:36 PM EST |
| Last Day Volume | 2,567,846 |
| Average Daily Volume | 4,106,064 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.24 |
| Last Price to 52 Week Low | 129.03% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 91.84 |
| Sector PE | 40.55 |
| 5-Year Average PE | 11.59 |
| Free Cash Flow Ratio | 5.46 |
| Industry Free Cash Flow Ratio | 14.88 |
| Sector Free Cash Flow Ratio | 29.46 |
| Current Ratio Most Recent Quarter | 1.98 |
| Total Cash Per Share | 0.52 |
| Book Value Per Share Most Recent Quarter | 0.11 |
| Price to Book Ratio | 25.45 |
| Industry Price to Book Ratio | 12.17 |
| Sector Price to Book Ratio | 32.17 |
| Price to Sales Ratio Twelve Trailing Months | 3.64 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.86 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.16 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 265,145,000 |
| Market Capitalization | 753,011,800 |
| Institutional Ownership | 43.30% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -33.67% |
| Reported EPS 12 Trailing Months | -0.18 |
| Reported EPS Past Year | 0.05 |
| Reported EPS Prior Year | -0.33 |
| Net Income Twelve Trailing Months | -36,484,000 |
| Net Income Past Year | -69,410,000 |
| Net Income Prior Year | -51,925,000 |
| Quarterly Revenue Growth YOY | 43.10% |
| 5-Year Revenue Growth | -13.72% |
| Operating Margin Twelve Trailing Months | 22.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 137,308,000 |
| Total Cash Past Year | 51,870,000 |
| Total Cash Prior Year | 42,925,000 |
| Net Cash Position Most Recent Quarter | 90,246,000 |
| Net Cash Position Past Year | 13,177,000 |
| Long Term Debt Past Year | 38,693,000 |
| Long Term Debt Prior Year | 17,183,000 |
| Total Debt Most Recent Quarter | 47,062,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.38 |
| Total Stockholder Equity Past Year | -49,185,000 |
| Total Stockholder Equity Prior Year | -30,584,000 |
| Total Stockholder Equity Most Recent Quarter | 29,224,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -2,578,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.01 |
| Free Cash Flow Past Year | -40,692,000 |
| Free Cash Flow Prior Year | -23,384,000 |
Options |
|
| Put/Call Ratio | 0.73 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.13 |
| MACD Signal | -0.12 |
| 20-Day Bollinger Lower Band | 2.48 |
| 20-Day Bollinger Middle Band | 3.32 |
| 20-Day Bollinger Upper Band | 4.17 |
| Beta | 1.02 |
| RSI | 34.86 |
| 50-Day SMA | 2.46 |
| 150-Day SMA | 1.55 |
| 200-Day SMA | 1.44 |
System |
|
| Modified | 9/18/2025 4:59:43 PM EST |